Compare CAMT & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAMT | LGND |
|---|---|---|
| Founded | 1987 | 1987 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 3.9B |
| IPO Year | 2000 | 1992 |
| Metric | CAMT | LGND |
|---|---|---|
| Price | $128.02 | $199.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | $121.08 | ★ $243.50 |
| AVG Volume (30 Days) | ★ 355.4K | 191.1K |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | ★ 0.76 |
| EPS | 1.01 | ★ 2.49 |
| Revenue | ★ $485,241,000.00 | $251,233,000.00 |
| Revenue This Year | $17.66 | $52.87 |
| Revenue Next Year | $6.37 | $6.07 |
| P/E Ratio | $130.77 | ★ $80.29 |
| Revenue Growth | 21.12 | ★ 64.83 |
| 52 Week Low | $47.41 | $93.58 |
| 52 Week High | $134.88 | $212.49 |
| Indicator | CAMT | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | 56.21 |
| Support Level | $106.13 | $186.48 |
| Resistance Level | $134.88 | $206.44 |
| Average True Range (ATR) | 4.34 | 5.91 |
| MACD | 2.57 | 0.52 |
| Stochastic Oscillator | 77.03 | 58.48 |
Camtek Ltd is engaged in the manufacturing of metrology and inspection equipment and software solutions for the semiconductor industry. Its systems inspect wafers for various semiconductor market segments, including Advanced Packaging, Heterogenous Integration (HI), Compound Semiconductors, Memory, and foundries among others. Geographically, it derives maximum revenue from China followed by Asia Pacific, Korea, United States, and Europe. The company's products and services include Surface Inspection, Bump Inspection and Metrology, and others.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.